These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1513185)

  • 1. Kala-azar: current status of experimental chemotherapy.
    Katiyar JC; Anuradha ; Sharma S
    Med Res Rev; 1992 Sep; 12(5):473-504. PubMed ID: 1513185
    [No Abstract]   [Full Text] [Related]  

  • 2. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
    Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
    Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Para-kala-azar dermal leishmaniasis in a patient in Brazil: a case report.
    Lindoso JAL; Moreira CHV; Celeste BJ; Oyafuso LKM; Folegatti PM; Zijlstra EE
    Rev Soc Bras Med Trop; 2018; 51(1):105-107. PubMed ID: 29513829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The experimental chemotherapy of leishmaniasis, V. The activity of potential leishmanicides against 'L. infantum LV9' in NMRI mice.
    Peters W; Trotter ER; Robinson BL
    Ann Trop Med Parasitol; 1980 Jun; 74(3):289-97. PubMed ID: 7396563
    [No Abstract]   [Full Text] [Related]  

  • 5. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
    J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leishmanin and tuberculin sensitivity in leishmaniasis in the Sudan, with special reference to kala-azar.
    Zijlstra EE; el-Hassan AM
    Trans R Soc Trop Med Hyg; 1993; 87(4):425-7. PubMed ID: 8249072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis).
    Thakur CP
    Trans R Soc Trop Med Hyg; 1984; 78(3):391-8. PubMed ID: 6087515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis.
    Zijlstra EE; Khalil EA; Kager PA; El-Hassan AM
    Br J Dermatol; 2000 Jul; 143(1):136-43. PubMed ID: 10886148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visceral leishmaniasis with concomittant post kala-azar dermal leishmaniasis responds to oral sitamaquine: case report.
    Mbui J; Rashid R; Lodenyo H; Nyakundi P; Kipmutai R; Mutuma G; Kirigi G; Kinoti D; Wasunna M
    East Afr Med J; 2003 Aug; 80(8):440-2. PubMed ID: 14601788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India.
    Thakur CP; Kumar A; Mitra G; Thakur S; Sinha PK; Das P; Bhattacharya SK; Sinha A
    Indian J Med Res; 2008 Jul; 128(1):38-44. PubMed ID: 18820357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dermal leishmaniasis after kala-azar infection: successful treatment with rifampin.
    Saha SK
    Cutis; 1985 Jul; 36(1):81-2. PubMed ID: 4017660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.
    Saha S; Mondal S; Ravindran R; Bhowmick S; Modak D; Mallick S; Rahman M; Kar S; Goswami R; Guha SK; Pramanik N; Saha B; Ali N
    J Immunol; 2007 Oct; 179(8):5592-603. PubMed ID: 17911647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post kala-azar ocular leishmaniasis.
    el Hassan AM; Khalil EA; el Sheikh EA; Zijlstra EE; Osman A; Ibrahim ME
    Trans R Soc Trop Med Hyg; 1998; 92(2):177-9. PubMed ID: 9764325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of the cell-mediated immune response in kala-azar and post-kala-azar dermal leishmaniasis in relation to chemotherapy.
    Neogy AB; Nandy A; Ghosh Dastidar B; Chowdhury AB
    Ann Trop Med Parasitol; 1988 Feb; 82(1):27-34. PubMed ID: 2840867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Splenectomy in kala-azar.
    Rees PH; Kager PA; Kyambi JM; Ayim EN; Bhatt KM; Schattenkerk JK
    Trop Geogr Med; 1984 Sep; 36(3):285-92. PubMed ID: 6506208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elimination of Kala-Azar from the Southeast Asia Region.
    Bhattacharya SK; Dash AP
    Am J Trop Med Hyg; 2017 Apr; 96(4):802-804. PubMed ID: 28115678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kala-azar (visceral Leishmaniasis) from Khotang.
    Joshi S; Bajracharya BL; Baral MR
    Kathmandu Univ Med J (KUMJ); 2006; 4(2):232-4. PubMed ID: 18603904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India.
    Das VN; Pandey K; Singh D; Forwood C; Lal CS; Das P
    J Postgrad Med; 2013; 59(3):226-8. PubMed ID: 24029204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive management of Indian visceral leishmaniasis: clinical application of diagnosis by K39 antigen strip testing at a kala-azar referral unit.
    Sundar S; Sahu M; Mehta H; Gupta A; Kohli U; Rai M; Berman JD; Murray HW
    Clin Infect Dis; 2002 Sep; 35(5):581-6. PubMed ID: 12173133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blindness following visceral leishmaniasis: a neglected post-kala-azar complication.
    Khalil EA; Musa AM; Younis BM; Elfaki ME; Zijlstra EE; Elhassan AM
    Trop Doct; 2011 Jul; 41(3):139-40. PubMed ID: 21676981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.